Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCV RNA ≥ 10,000 IU/mL at screening~* HCV genotype 1 or 4~* HIV-1 infection~* Cirrhosis determination, a fibroscan or liver biopsy may be required~* Screening laboratory values within defined thresholds~* Use of protocol specified method(s) of contraception if female of childbearing potential or sexually active male~Exclusion Criteria:~* Clinically-significant illness (other than HCV or HIV) or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol~* Current or prior history of clinical hepatic decompensation, hepatocellular carcinoma (HCC), or other malignancy (with the exception of certain resolved skin cancers)~* Hepatitis B virus (HBV) infection~* Pregnant or nursing female~* Chronic use of systemically administered immunosuppressive agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 12 Weeks (Type: EXPERIMENTAL): LDV/SOF for 12 weeks
- Retreatment Substudy (Type: EXPERIMENTAL): LDV/SOF plus RBV for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).